P rogrammed cell removal (PrCR) is a process of macrophagemediated immunosurveillance by which target cells are recognized and phagocytosed (1) . PrCR previously was known to be a key step concurrent with programmed cell death for the clearance of apoptotic cells, but when apoptosis is blocked, PrCR of neutrophils that are living (because of the enforced expression of bcl2) occurs precisely at the same time that PrCR removes dying wild-type neutrophils (2) . Recently a role for PrCR in eliminating living tumor cells has been revealed (1) . Several studies have indicated a crucial function of CD47 as an antiphagocytic don't-eat-me signal dominating over PrCR (3) (4) (5) (6) (7) (8) (9) (10) . During cancer development, tumor cells up-regulate CD47, which protects them from PrCR (1, 3, 4, 6) . Blockade of the interaction between CD47 on target cells and its receptor, signal-regulatory protein α (SIRPα), on macrophages elicits efficient PrCR of cancer cells but not of most normal cells in vitro and in vivo (Fig. 1A) (1, 3) . When CD47 is blocked, cancer cells, but not normal cells, are phagocytosed because prophagocytic eat-me signals such as calreticulin (CRT) are commonly expressed on many leukemias, lymphomas, and solid tumors (Fig. 1A) (11) . CRT normally is an endoplasmic reticulum (ER) protein possessing ER retention KDEL sequences but can be released to the cell surface in many instances of cell damage by cytotoxic drugs or inflammation and is recognized by macrophage LRP1/CD91 during phagocytosis of apoptotic cells (12, 13 ). Bruton's tyrosine kinase (Btk) is a member of the Tec nonreceptor protein tyrosine kinase family, which plays a crucial role in the regulation of the innate immune response (14, 15) . A defect of Btk leads to immunodeficiencies including X-linked hypo-or agammaglobulinemia (16) (17) (18) , presumably caused by the blockade of B-cell development and perhaps related to inefficient clearance of defective B-lineage cells as well (19) . Thus far, however, little is known about the molecular mechanisms by which macrophages recognize and phagocytose living cancer cells. We show here that macrophages express CRT and that Toll-like receptor (TLR) signaling through Btk results in its trafficking to the cell surface, where it can be used to mediate PrCR of appropriate tumor cells.
Results
We performed phagocytosis assays by coculturing mouse bone marrow-derived macrophages (BMDMs) and target human cancer cells to examine the efficacy of PrCR under different conditions. To induce phagocytosis, we blocked CD47 on a human colon cancer cell line (SW620) either by treating tumor cells with CD47-blocking antibodies or by directly knocking out CD47. Phagocytosis was increased significantly by knocking out the selfprotective signal CD47 (SW620 CD47KO ) ( Fig. S1 ) resulting from an imbalance of eat-me over don't-eat-me pathways (Fig. 1A) .
Treatment of SW620
WT cells with anti-CD47 antibody elicited stronger phagocytosis which was reversed by Fc-receptor blockers to the same level as that of SW620 CD47KO cells, suggesting that anti-CD47 antibody induced phagocytosis of SW620 cancer cells by both Fc-independent (blockade of CD47-SIRPα interactions) and Fc-dependent mechanisms (Fig. 1A) .
To understand the molecular mechanisms of PrCR, we performed screening experiments to identify signaling pathways that regulate the phagocytic ability of macrophages. TLR signaling plays a crucial role in the innate immune response against Significance Macrophage-mediated programmed cell removal (PrCR) plays an essential role in tumor surveillance and elimination. Blockade of the don't-eat-me signal CD47 on tumor cells allows already expressed eat-me signals to induce PrCR to eliminate tumor cells. To date the molecular mechanism by which macrophages recognize and phagocytose tumor cells remains unclear. This paper demonstrates that the activation of Toll-like receptor (TLR) pathways in macrophages induces the phosphorylation of Bruton's tyrosine kinase (Btk), which catalyzes cell-surface exposure of calreticulin. Calreticulin on or secreted by macrophages plays a critical role in mediating adjacent tumor cell recognition and phagocytosis. These findings reveal a strategy to enhance the efficacy of PrCR through a combination of TLR/Btk activation and CD47 blockade, and advance our understanding of the underlying mechanism of macrophagemediated PrCR of tumor cells. pathogens (20, 21) , and TLR agonists are listed as immunotherapeutic agents with anticancer potential (22) . However, the role of TLR signaling in PrCR of living cancer cells remains unexplored. Thus, we pretreated BMDMs with various TLR agonists and then assayed their phagocytotic ability against cancer cells. We found that the activation of multiple TLRs significantly enhanced phagocytosis of cancer cells (Fig. 1B) . We next focused on the TLR agonists that were most effective at enhancing phagocytosis, assessing their effects on a wider range of macrophages and tumor cells. We showed that treatment of macrophages with TLR3, -4, and -7 agonists, i.e., high-molecular-weight polyinosinic-polycytidylic acid [poly (I:C) HMW], LPS, and imiquimod, dramatically enhanced their phagocytosis of multiple hematopoietic and solid tumor cells (Figs. S2 and S3). Subsequent assessment in mice lacking T, B, and natural killer (NK) cells showed that these TLR agonists significantly improved the efficacy of CD47-blocking antibody in blocking tumor growth in vivo (Fig. S4) .
To understand further the mechanism by which the activation of TLR signaling in macrophages promoted tumor cell phagocytosis, we treated macrophages by combining TLR agonists with various inhibitors targeting key molecules that positively (MAPK, Btk) (23) (24) (25) (26) (27) or negatively (PI3K, caspase-1) (28, 29) regulate TLR signaling. Blockers of MAPK, PI3K, and caspase-1 showed no effect on phagocytosis of cancer cells. In contrast, ibrutinib, a specific blocker of Btk, a tyrosine kinase expressed in the hematopoietic system ( Fig. S5) (15, 30, 31) , significantly attenuated phagocytosis induced by TLR agonists ( Fig. 2A) . Treatment of macrophages with poly (I:C) HMW, LPS, or imiquimod stimulated Btk to be phosphorylated, and this effect was counteracted by ibrutinib, resulting in basal Btk phosphorylation (Fig.   2B ). Notably, basal-level phagocytosis of cancer cells was regulated by the Btk pathway, and ibrutinib showed an inhibitory effect on both Fc-dependent and -independent phagocytosis (Fig. S6A ). In sum, Btk is a crucial effector through which TLRs mediate tumor cell phagocytosis. Interestingly, stimulation and inhibition of Btk showed differential temporal effects on phagocytosis. Maximal phagocytic ability of macrophages was achieved with 16 h of Btk activation (Fig. 2C) ; in contrast, blockade of Btk showed a prompt effect and reached the maximal inhibition within 1 h (Fig. 2D) .
Upon activation, Btk phosphorylates transcription factors such as TFII-I and STAT5A (32, 33) in the nucleus and PLCγ2 (34) at the plasma membrane. Recent studies identified CRT as a substrate phosphorylated by Btk when TLR7 was activated in the recognition of apoptotic cells (35) . Phosphorylation of CRT by Btk in macrophages was important for CRT trafficking to the cell surface to function as a bridging molecule in the CRT/CD91/C1q complex, which initiates phagocytosis of apoptotic cells (13, 35, 36) . To investigate whether CRT is the critical downstream effector of the TLR-Btk pathway to mediate PrCR of tumor cells, we then examined the expression and function of CRT in macrophages. We found that CRT was expressed on the surface of macrophages, and its cell-surface exposure was regulated by the activation status of Btk (Fig. 3 A and B and Fig. S6B ). CRT antibody significantly inhibited phagocytosis of SW620 cells by mouse BMDMs or human peripheral blood mononuclear cells (PBMC)-derived macrophages ( Fig. 3C and Fig. S6 C and D) , whereas overexpression of CRT in a mouse monocyte/macrophage cell line, J774, led to enhanced phagocytosis (Fig. 3D ). In addition, we confirmed phosphorylation of CRT upon Btk activation, which reached the maximal level after 30 min of imiquimod treatment of macrophages (Fig. S6E) . These results suggest that CRT is an essential component regulated by the TLRBtk pathway to mediate phagocytosis of living cancer cells.
We further dissected the role of CRT in mediating PrCR of cancer cells. Previous studies demonstrated cell-surface expression of CRT on apoptotic cells and multiple viable human cancer cells (Fig. S7 B-D) (11, 12) . Thus, we examined whether CRT plays a critical role in mediating cancer cell phagocytosis on both macrophages and target tumor cells (Fig. 4A) . Interestingly, blockade of CRT on macrophages diminished phagocytosis, but blocking CRT on cancer cells showed no effect, suggesting that CRT has a specific role in mediating phagocytosis on macrophages (Fig. 4A) . Importantly, cell-surface expression of CRT was enhanced by TLR agonists in macrophages but not in target cancer cells, which lack Btk (Fig. S7) , indicating distinct mechanisms regulating CRT exposure. Next, we examined macrophage subpopulations with different levels of cell-surface CRT and found that macrophages with a higher surface CRT showed a stronger phagocytic ability (Fig. 4B and Fig. S8 A and B) . Quantitative analysis of a panel of macrophages, including subpopulations with differential surface CRT expression and macrophages at different time points after imiquimod treatment, revealed a significant correlation between CRT expression on macrophages and tumor cell phagocytosis (Fig. 4C and Fig. S8 C  and D) . Additionally, both M1 and M2 human macrophages (37, 38) derived from the peripheral blood expressed CRT on the surface, and an M1 subset expressed a somewhat higher level of CRT (Fig. S9) . Taken together, these findings indicate that CRT is a key effector for macrophage-mediated surveillance of tumor cells and that enhanced PrCR of cancer cells can be achieved by up-regulating CRT on macrophages.
Discussion
Recent progress in cancer immunology has highlighted the ability of cancer cells to evade immunosurveillance as one of the essential hallmarks of cancer (1, 39, 40) . Although lymphocytes (T, B, and NK cells) have been thought to mediate the bulk of anticancer immunosurveillance (41), we have demonstrated that blockade of CD47 on tumor cells leads to in vivo immune recognition, macrophage phagocytosis of tumor cells, and tumor elimination in mice deficient in lymphocytes, indicating that phagocytes are crucial to surveillance against cancer cells (40) . Phagocytosis of tumor cells mediated by anti-CD47 blockade can result in cross-presentation of tumor antigens to CD8 T cells, so that CD47 blockade can result in both innate immune system macrophage surveillance and stimulation of adaptive immune system T-cell cytotoxicity (42) . Here we show that cell-surface expression of CRT on macrophages is controlled by the TLRBtk pathway, which induces the phosphorylation of CRT for its cleavage from the ER retention signals and subsequent secretion and binding to CD91 on the cell surface. We show that this mechanism of secretion is important for mediating PrCR of live cancer cells and also removes apoptotic cells (35) . CRT on macrophages may function in detecting target cells through trans interaction with as yet unidentified specific receptors on target cancer cells; thus blockade of surface CRT inhibits PrCR. Moreover, CD47 mutant mice do not phagocytose self red cells or hematopoietic stem cells; however, these cells are phagocytosed rapidly when transferred to wild-type congenic normal or irradiated mice (3, 43) , even though neither cell type expresses CRT in microarrays, indicating that other eat-me signals may be used or that CRT can decorate target cells that do not express CRT genes. We show that multiple types of TLR agonists are able to stimulate macrophages and enhance PrCR of solid tumor cells, as is consistent with reports that the TLR4 agonist LPS and IFN-γ receptors are necessary for activating macrophages to phagocytose acute myeloid leukemia cells after the CD47-SIRPα interaction is disrupted (44) . These studies suggest that TLR signaling can synergize with anti-CD47 blockade to enhance tumor cell phagocytosis and therefore modulating TLR signaling could be a therapeutic approach to enhance tumor cell elimination. Notably, the impact of modulating TLR signaling in normal cells in the context anti-CD47 blockade must be tested . Tumor cells were transduced with lentiviruses which were generated with a pCDH-CMV-MCS-EF1 lentiviral vector expressing a luciferase-eGFP fusion protein and were sorted by flow cytometry with BD FACSAria II cell sorters for GFP + cells, as described previously (6) .
CD47 Knockout with Transcription Activator-Like Effector Nucleases. Transcription activator-like effector nucleases (TALENs) were designed and assembled as described (45) . The genomic locus of human CD47 (NC_000003.12) was scanned for putative TALEN-binding pairs. Exon 2 ultimately was selected for targeting, and the TALEN pairs TGTCGTCATTCCATGCTTTG and TATA-CTTCAGTAGTGTTTTG were cloned respectively into the pTALEN backbone. SW620 cells were transfected with the CD47-TALEN constructs using Lipofectamine 2000. Three days after transfection, cells were stained with anti-CD47 or isotype antibodies. CD47 − cells were sorted by flow cytometry with BD FACSAria II cell sorters.
Preparation of Macrophages. BMDMs were generated as previously described (3) . Briefly, bone marrow cells were isolated from BALB/c, NSG, or RAG2 
